Todor Dentchev is an Oncology physician affiliated with Altru Health System. OpenAlex indexes 14 publications with 606 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
960 S Columbia Rd - Altru Cancer Center
Grand Forks, ND 58201
Telephone
701-780-5400Provider last certified this registry record 9 Jun 2020.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20253 payments
- AstraZeneca Pharmaceuticals LPProgram year20225 payments
- Novartis Pharmaceuticals CorporationProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
34.7%Aromatase Inhibitor18.8%Anastrozole70%Letrozole30%Part D<11 patientsThalidomide Analog3.6%Lenalidomide52%Revlimid48%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
23.8%Serotonin-3 Receptor Antagonist10.1%Ondansetron Hcl100%Part D≥46 patientsCorticosteroid6.9%Prednisone100%Part D≥16 patients+ 2 more classes in this area
Nervous system
17.3%Phenothiazine8.5%Prochlorperazine Maleate100%Part D≥56 patientsOpioid Agonist3.3%Oxycodone-Acetaminophen58%Oxycodone Hcl42%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I
Supportive Care in Cancer
2017 - Pilot Study of Minocycline for the Prevention of Paclitaxel-Associated Neuropathy: ACCRU RU221408I (FR420C)
Journal of Pain and Symptom Management
2017 - Pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU RU221408I.
Journal of Clinical Oncology
2016 - Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7
Journal of Clinical Oncology
2010
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”